



Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

How to improve efficacy-future challenges

Málaga, Spain
15-16 November 2024

Preliminary Programme

Thursday, 14 November 2024

**17:30 - 19:00 Paediatric Diseases Working Party & Transplant Complications Working Party
Business Meetings**

Friday, 15 November 2024

09:00 - 09:10 Welcome from the organizers

09:10 - 10:55 Session I: Patient journey through CAR-T therapies: panel discussion

The session will cover the risk factors for failed CAR-T production, bridging therapies, risk factors for immune complications, risk factors for non-immune complications, aspects of doctor-patient interaction when consulting a patient, options for choosing a particular product in different countries, and aspects of follow-up.

10:55 - 11:25 Coffee Break

11:25 - 13:00 Session II: Supportive care and monitoring

11:25 - 12:25 Prophylaxis of cytokine release syndrome: pro and contra

The part of the session will cover the existing body of evidence on using prophylaxis in CAR-T recipients and the selection of patients for such prophylaxis. The spectrum of potential target therapies for prophylaxis will be covered.

12:25 - 13:10 Supportive care and monitoring: panel discussion

In this part of the session, the presenters will describe the existing recommendations on supporting care and evaluation of symptoms at various stages after CAR-T therapies. The necessary minimum of laboratory and instrumental workouts will be described.

13:10 - 14:10 Lunch Break

For further information, please contact education.events@ebmt.org

14:10 - 15:50 Session III: Cytokine release syndrome after CAR-T therapies

The session is intended to teach the spectrum of clinical manifestations of CRS, the necessary laboratory and instrumental confirmatory studies, potential histological findings, and differences in presentation in the pediatric and adult populations. The treatment part will cover the optimal timing for initiation of therapy, first and subsequent lines of therapy, and evaluation of response.

- 14:10 - 14:40 A spectrum of clinical presentations and treatment in pediatric patients
- 14:40 - 15:10 A spectrum of clinical presentations and treatment in adult and elderly patients
- 15:10 - 15:30 CRS case presentation from abstract and discussion
- 15:30 - 15:50 CRS case presentation from abstract and discussion

15:50 - 16:20 Coffee Break

16:20 - 17:05 Industry Symposium

17:05 - 18:35 Session IV: Neurologic complications of CAR-T therapies

The session focuses on tools to monitor for ICANS and other manifestations of neurotoxicity, and the utility of imaging methods. Treatment overview will include corticosteroids, anti-cytokine, and anticonvulsant therapies. After the session, the attendees will be able to implement monitoring and early intervention protocols in their hospitals.

- 17:05 - 17:35 Emerging strategies for managing ICANS
- 17:35 - 17:55 non-ICANS neurological complications
- 17:55 - 18:15 Managing patients with central nervous system involvement
- 18:15 - 18:35 Fludarabine-related neurotoxicity: truth or myth?

Saturday, 16 November 2024

09:00 - 10:00 Session V: Infectious complications after CAR-T therapy

This session will provide an overview of recommendations on prophylaxis, current clinical practice, and recommendations on empirical antibacterial and antifungal therapies. The session will also cover difficulties of identifying patients with infections after anti-cytokine therapies, and practical recommendations on antimicrobial therapy in difficult diagnostic situations.

09:00 - 09:20 Current recommendations on prophylaxis of infections after CAR-T therapies

09:20 - 09:40 Differential diagnosis of sepsis and CRS, principles of empirical antimicrobial therapy after CAR-T therapies

09:40 - 10:00 Case presentation from abstracts and discussion

10:00 - 10:45 Industry Symposium

10:45 - 11:15 Coffee Break

11:15 - 13:15 Session VI: Rare CAR-T complications

The session will discuss rare cases of complications after CAR-T therapies, like HLH/MAS, late cytopenia, graft-versus-host disease, pseudo progression and TA-TMA, as well as approaches to their treatment.

11:15 - 11:35 Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) after CAR-T: differential diagnosis from “common” CRS

11:35 - 11:55 Cytopenia after CAR-T: clinical presentation and treatment

11:55 - 12:15 TA-TMA after CAR-T therapies

12:15 - 12:35 Late complications after CAR-T therapies

12:35 - 13:15 “Never give up until you really have to” - case presentation and discussion

13:15 - 13:30 Summary and Farewell